期刊文献+

^(18)F-ML-10监测多柔比星诱发心脏毒性的可行性探讨

Feasibility of using ^(18)F-ML-10 to monitor cardiotoxicity induced by doxorubicin
下载PDF
导出
摘要 目的探讨放射性核素凋亡显像剂^(18)F-ML-10无创监测多柔比星诱发心脏毒性的可行性。方法 36只KM小鼠随机分为对照组、低剂量(15 mg/kg)多柔比星模型组和高剂量(20 mg/kg)多柔比星模型组,每组12只。对照组腹腔注射生理盐水,多柔比星模型组腹腔注射一定剂量的多柔比星,48 h后进行小动物超声检测左室射血分数(left ventricular ejection fraction,LVEF),以及放射性显像剂^(18)F-ML-10与^(18)F-FDG在小鼠体内的生物分布并测定每克组织放射性摄取值(%ID/g),处死的小鼠取出心脏进行caspase 3免疫组化检测心肌细胞的凋亡情况。结果超声结果显示低剂量组[LVEF=(59.49±5.32)%]与高剂量组LVEF=(52.41±6.47)%小鼠左室射血分数明显低于对照组LVEF=(70.58±5.06)%,^(18)F-FDG在低剂量组(%ID/g=21.67±3.69)与高剂量组(%ID/g=15.58±1.92)的摄取也明显低于对照组(%ID/g=36.18±3.65),而凋亡显像剂^(18)F-ML-10在低剂量组(%ID/g=0.50±0.11)与高剂量组(%ID/g=1.100.55)的摄取明显明显高于对照组(%ID/g=0.02±0.02),差异均有统计学意义(P<0.05),caspase 3免疫组化显示模型组心肌细胞发生明显凋亡,与^(18)F-ML-10在心脏的摄取相一致。结论心肌细胞的凋亡是多柔比星诱导心脏毒性的重要途径,特异性凋亡显像剂^(18)F-ML-10用于多柔比星诱发心肌细胞凋亡的毒性监测具有较好的应用前景。 Objective To investigate the feasibility of noninvasive monitoring of doxorubicin-induced cardiotoxicity by radionuclide apoptosis imaging agent ISF-ML-10. Methods Thirty-six KM mice were randomly and equally divided into control group, low dose (15 mg/kg) model group and high dose (20 mg/kg) model group. The mice in control group were injected with normal saline. Doxorubicin was injected into model group at some dose. After 48 hours, mice were subjected to cardiac uhrasonography and the biodistribution of ^18F-FDG and ^18F-ML-10 was determined with gamma counting. The mice were sacrificed to remove the heart for caspase 3 immunohistochemical detection of myocardial cell apoptosis. Results The left ventricular ejection fraction was significantly lower in low dose group ( LVEF = 59.49 ± 5.32% ) and high dose group ( LVEF = 52.41 ± 6.47% ) than that in control group ( LVEF = 70.58 ± 5.06% ), but the uptake of ^18F-FDG in low dose group ( % ID/g = 0.50 ± 0.11 ) and high dose group ( % ID/g = 15.58 ± 1.92) was significantly lower than that in control group ( % ID/g = 36.18 ± 3.65 ). The uptake of apoptotic imaging agent ^18F-ML-10 in low dose group ( % ID/g =0.50 ±0.11 ) and high dose group( % ID/g = 1.10 ± 0.55 ) was significantly higher than that in control group ( % ID/g =0O. 02 ± 0. 02 ) ( P 〈 0. 05 ). Caspase 3 immunohistochemistry showed obvious apoptosis of myocardial ceils in model group, which was consistent with the uptake of 18F-ML-10 in the heart. Conclusions Apoptosis is an important pathway for doxorubicin-induced cardiotoxicity, ^18F-ML-10 may contribute to the detection of doxorubicin-induced myocardial apoptosis.
出处 《武警医学》 CAS 2017年第3期227-231,共5页 Medical Journal of the Chinese People's Armed Police Force
基金 天津市自然科学基金资助项目(13JCYBJC22000) 武警后勤学院附属医院种子基金资助项目(FYQ201601)
关键词 多柔比星 心脏毒性 凋亡 18F-ML-10 doxorubicin cardiotoxicity apoptosis ^18F-ML-10
  • 相关文献

参考文献1

二级参考文献7

  • 1王子平,孙燕,张湘茹,张茂宏,王秀问,于学军,南克俊,李恩孝,刘基巍,高亚杰,关小倩,宋恕平,盛立军,王东林,王志新.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2006,28(6):468-470. 被引量:70
  • 2Mathew J, Asgeirsson K S, Agrawal A, et al. Neoadju- rant chemotherapy in locally advanced primary breast cancers : the Nottingham experience [ J ]. Eur J Surg On- col, 2007, 33(8) : 972-976. 被引量:1
  • 3Rastogi P, Anderson S J, Bear H D, et al. Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [ J ]. J Clin Oncol, 2008, 26(16) : 778-785. 被引量:1
  • 4Gupta D, Raina V, Rath G K, et al. Clinical and patho- logical response rates of docetaxel-based neoadjuvant che- motherapyin locally advanced breast cancer arid compari- son with anthracycline-based chemotherapies: eight-year experience from single centre [J ]. Indian J Cancer, 2011,48(4) : 410-414. 被引量:1
  • 5Von Minckwitz G, Kummel S, Vogel P, et al. Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study [ J ]. J Natl Cancer Inst, 2008, 100(8) : 552-562. 被引量:1
  • 6Phua C E, Bustam A Z, Yusof M M, et al. Risk of treat- ment related death and febrile neutropaenia with taxane- based adjuvant chemotherapy for breast cancer in a mid- die income country outside a clinical trial setting [ J ]. A- sian Pac J Cancer Prev, 2012, 13(9) : 4623-4626. 被引量:1
  • 7Gianni L, Eiermann W, Semiglazov V, et al. Neoadju- vant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast canc- er (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort [ J ]. Lancet, 2010, 375(9712) :377-384. 被引量:1

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部